These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 39107835)

  • 1. Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies.
    Zhang X; Wang J; Zhang Z; Ye K
    Transl Neurodegener; 2024 Aug; 13(1):40. PubMed ID: 39107835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular and pathological heterogeneity of primary tauopathies.
    Chung DC; Roemer S; Petrucelli L; Dickson DW
    Mol Neurodegener; 2021 Aug; 16(1):57. PubMed ID: 34425874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief update on different roles of tau in neurodegeneration.
    Ittner A; Ke YD; van Eersel J; Gladbach A; Götz J; Ittner LM
    IUBMB Life; 2011 Jul; 63(7):495-502. PubMed ID: 21698753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Prion-like" templated misfolding in tauopathies.
    Clavaguera F; Lavenir I; Falcon B; Frank S; Goedert M; Tolnay M
    Brain Pathol; 2013 May; 23(3):342-9. PubMed ID: 23587140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau Protein and Zebrafish Models for Tau-Induced Neurodegeneration.
    Ding Y; Lei L; Lai C; Tang Z
    J Alzheimers Dis; 2019; 69(2):339-353. PubMed ID: 31006683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration.
    Li W; Li JY
    Transl Neurodegener; 2024 Mar; 13(1):16. PubMed ID: 38528629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain microRNAs dysregulation: Implication for missplicing and abnormal post-translational modifications of tau protein in Alzheimer's disease and related tauopathies.
    Bazrgar M; Khodabakhsh P; Mohagheghi F; Prudencio M; Ahmadiani A
    Pharmacol Res; 2020 May; 155():104729. PubMed ID: 32126270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tauopathies as clinicopathological entities.
    Irwin DJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(0 1):S29-33. PubMed ID: 26382841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau Abnormalities and the Potential Therapy in Alzheimer's Disease.
    Almansoub HAMM; Tang H; Wu Y; Wang DQ; Mahaman YAR; Wei N; Almansob YAM; He W; Liu D
    J Alzheimers Dis; 2019; 67(1):13-33. PubMed ID: 30507581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying strategies in primary tauopathies.
    Rösler TW; Costa M; Höglinger GU
    Neuropharmacology; 2020 May; 167():107842. PubMed ID: 31704274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies.
    Lo CH; Lim CK; Ding Z; Wickramasinghe SP; Braun AR; Ashe KH; Rhoades E; Thomas DD; Sachs JN
    Alzheimers Dement; 2019 Nov; 15(11):1489-1502. PubMed ID: 31653529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies.
    Ferreira A; Bigio EH
    Mol Med; 2011; 17(7-8):676-85. PubMed ID: 21442128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
    Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
    Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
    Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
    Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers.
    Quinn JP; Corbett NJ; Kellett KAB; Hooper NM
    J Alzheimers Dis; 2018; 63(1):13-33. PubMed ID: 29630551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of tau protein in health and disease.
    Guo T; Noble W; Hanger DP
    Acta Neuropathol; 2017 May; 133(5):665-704. PubMed ID: 28386764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.
    Williams DR
    Intern Med J; 2006 Oct; 36(10):652-60. PubMed ID: 16958643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tauopathies and tau oligomers.
    Takashima A
    J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders.
    Kaur P; Khera A; Alajangi HK; Sharma A; Jaiswal PK; Singh G; Barnwal RP
    Mol Neurobiol; 2023 Mar; 60(3):1690-1720. PubMed ID: 36562884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tauopathies: Mechanisms and Therapeutic Strategies.
    Tan CC; Zhang XY; Tan L; Yu JT
    J Alzheimers Dis; 2018; 61(2):487-508. PubMed ID: 29278892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.